Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The pandemic is testing our societal structures like never before. To deal with it successfully, we need to think and act collectively, led by our key institutions. But at a time when unity is critical, are we about to see the effects of a long-standing and corrosive drip feed of mistrust?

Nurse discussing vaccination with female patient

The rapid development and testing of COVID-19 vaccines has been an extraordinary scientific undertaking. What happens now is arguably even more important: to ensure the vaccines are an effective intervention, people will need to take them. The practical challenges of manufacturing and dispensing millions of doses worldwide are of course immense, but societies also have to deal with the issue of vaccine hesitancy: the belief that a vaccine may be unnecessary, ineffective, or unsafe (and perhaps all three). Unsurprisingly, people who have these concerns may be reluctant to take a vaccine; they may even refuse it outright.

Vaccine hesitancy isn’t new. However, the pandemic has created the ideal conditions for mistrust of a COVID-19 vaccine to thrive. Part of the problem is the complexity and variability of transmission and infection. The fact that you may not catch the virus if you break social distancing guidelines and that the illness may be mild if you do get it, has led some to conclude that there isn’t a real problem. The unprecedented speed with which the vaccines have been developed has also provoked worry: there are concerns that safety has been compromised or that the vaccine will be rolled out before we understand the extent and nature of possible side effects. Moreover, the Internet is awash with misinformation -- including conspiracy theories – about the virus, lockdown, and vaccinations.

Read the full blog on the University of Oxford website

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.